Table 2.
Outpatient HIV and SARS‐CoV‐2 coinfection in Rhode Island
| Pt 1 | Pt 2 | Pt 3 | Pt 4 | Pt 5 | Pt 6 | Pt 7 | Pt 8 | Pt 9 | Pt 10 | Pt 11 | Pt 12 | Pt 13 | Pt 14 | Pt 15 | Pt 16 | Pt 17 | Pt 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General | ||||||||||||||||||
| Sex | Male | Male | Female | Female | Male | Male | Male | Male | Female | Male | Male | Male | Male | Male | Male | Male | Female | Female |
| Age (years) | 62 | 37 | 57 | 51 | 32 | 53 | 48 | 38 | 37 | 57 | 56 | 44 | 54 | 37 | 30 | 42 | 47 | 51 |
| Race/ethnicity | White; non‐Hispanic | White; non‐Hispanic | Other | Hispanic | Hispanic | White; non‐Hispanic | AA | White; non‐Hispanic | AA | Hispanic | Hispanic | Hispanic | Hispanic | Hispanic | White; non‐Hispanic | Hispanic | AA | AA |
| HIV | ||||||||||||||||||
| Dx year | 2015 | 2012 | 2015 | 2001 | 2012 | 2009 | 2002 | 2013 | 2015 | 2017 | 2001 | 2014 | 2010 | 2010 | 2019 | 2005 | 2009 | 2017 |
| Current ART | BTG/FTC/TAF | BTG/FTC/TAF | BTG/FTC/TAF | DTG/RPV | BTG/FTC/TAF | EVG/c/FTC/TAF | EVG/c/FTC/TAF | EVG/c/FTC/TAF | EVG/c/FTC/TAF | BTG/FTC/TAF | BTG/FTC/TAF | BTG/FTC/TAF | BTG/FTC/TAF | BTG/FTC/TAF | BTG/FTC/TAF | BTG/FTC/TAF | DVR/c/FTC/TAF | BTG/FTC/TAF |
| VL (copies/mL) a | <20 | 69 | <20 | <20 | <20 | <20 | 46 | <20 | <20 | <20 | <20 | 46 | <20 | <20 | <20 | <20 | <20 | <20 |
| CD4 count a (cells/µL) | 746 | 789 | 216 | 746 | 346 | 683 | 1375 | 760 | 644 | 1441 | 444 | 357 | 813 | 638 | 459 | 743 | 347 | 239 |
| CD4% a | 23 | 35 | 16 | 21 | 19 | 34 | 35 | 30 | 27 | 53 | 27 | 14 | 36 | 32 | 36 | 18 | 32 | 16 |
| Time CD4> 200 | Since 2015 | Since 2017 | Since 2015 | Since 2012 | Since 2016 | Since 2010 | Since 2003 | Since 2016 | Since 2015 | Since 2017 | Since 2002 | Since 2016 | Since 2010 | Since 2011 | Since 2019 | Since 2006 | Since 2009 | Since 2017 |
| COVID‐19 | ||||||||||||||||||
| Risk factors | Works in homeless Shelter | Contact with + cases | Contact with + cases | None | Contact with + cases | Contact with + cases; travel | Contact with + cases | Healthcare worker | None | None | Contact with + cases | Healthcare worker | Contact with + cases | Contact with + cases | None | None | Works in group home | Healthcare worker |
| Other Co‐morbidities | HTN | Obesity | DM | DM, asthma | HLH in remission, Histo‐plasmosis | HTN | HTN | Obesity | None | None | HTN, obesity | Obesity | HTN, CAD | Alcoholism, cirrhosis | None | None | None | Obesity |
| Active tobacco use | No | No (former smoker) | No | No (former smoker) | No (former smoker) | Yes | No | No (former smoker) | No | No | No | No (former smoker) | No | No (former smoker) | Yes | No | No | No |
| Symptoms | Cough, fever, low appetite | Cough, fever, myalgia | None | Fever, myalgia, HA, chills | Fever, cough, sore throat | Anosmia, nasal cong | Fatigue, nasal cong, HA | Myalgia, back pain | HA | HA, myalgia, anosmia | HA, myalgia, anosmia | Myalgia, back pain | Lethargy, anosmia | SOB, fever, myalgia | Anosmia | Cough, myalgia | Fever, cough | HA, back pain |
| Symptoms pre‐testing | 14 days | 2 days | N/A | 1 day | 3 days | weeks | 4 days | 3 days | Unknown | 7 days | Unknown | 5 days | Unknown | Unknown | Unknown | 9 days | Unknown | 4 days |
| Min RA O2% | 96% | 98% | N/A | 98% | N/A | N/A | N/A | N/A | N/A | 97% | N/A | 95% | N/A | 95% | N/A | N/A | N/A | 99% |
| ALC (109/L) b | 2200 | 800 | N/A | 1800 | N/A | N/A | N/A | N/A | N/A | 1400 | N/A | 2200 | N/A | 2100 | N/A | N/A | N/A | 1600 |
| CRP (mg/L) c | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 180 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Ferritin (ng/mL) c | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 412 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| D‐dimer (ng/mL) c | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 142 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| ALT (IU/L) c | N/A | 14 | N/A | 25 | N/A | N/A | N/A | N/A | N/A | 24 | N/A | N/A | N/A | 61 | N/A | N/A | N/A | 10 |
| AST IU/L) c | N/A | 31 | N/A | 21 | N/A | N/A | N/A | N/A | N/A | 30 | N/A | N/A | N/A | 71 | N/A | N/A | N/A | 18 |
| LDH (IU/L) c | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 245 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| HCV status | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Cured | Neg |
| Imaging | CXR: mild ist asd | CXR: clear lungs | N/A | CXR: RUL asd | N/A | N/A | N/A | N/A | N/A | CXR: BL asd | N/A | CXR: BL asd | N/A | CXR: ist asd | N/A | N/A | N/A | Neg |
| COVID‐19 therapy | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Outcome | DC from ED | DC from ED | Home | DC from ED | Home | Home | Home | Home | Home | Home | Home | DC from ED | Home | Home | Home | Home | Home | Home |
/c, cobicistat; +, positive; 3TC, lamivudine; AA, African American; ABC, abacavir; ALC, absolute lymphocyte count; ART, antiretroviral therapy; asd, air space disease; BL, bilateral; BTG, bictegravir; CD4 count/ VL are prior to COVID‐19 infection; cong, congestion; CT, computerized tomography; CVA, cerebrovascular accident; CXR, chest X‐ray; DC, discharge; DM, diabetes mellitus, DRV, darunavir; DTG, dolutegravir; dx, diagnosis; ED, emergency department; EFV, efavirenz; ESRD, end stage renal disease; EVG, elvitegravir; FTC, emtricitabine; HA, headache; HCV, hepatitis C virus; HLD, hyperlipidaemia; HLH, haemophagocytic lymphohistiocytosis; HTN, hypertension; ICU, intensive care unit; IST, interstitial; mf, multifocal; Min, minimal; N/A, not available; Neg, negative; O2, oxygen; Pt, patient; RA, room air; RDV, remdesivir; RPV, rilpivirine; RUL, right upper lobe; Sat, saturation; SOB, shortness of breath; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate, VL, viral load.
Before COVID‐19
lowest recorded
highest recorded.